soul trial oral semaglutide cardiovascular outcomes 2024 results 2025 nejm Oral Semaglutide's Impact on Cardiovascular Events in Type 2 Diabetes Patients with Cardiovascular and Kidney Disease: SOUL Trial Results Semaglutide cardiovascular outcomes align more

Pros: Less invasive than surgery

Common Side Effects for Both Compounds: The high prevalence of gastrointestinal adverse events with each compound individually suggests that combining them could potentially result in: More severe nausea and vomiting episodes Higher discontinuation rates Reduced treatment adherence Potential nutritional deficiencies from excessive appetite suppression Dehydration risks from combined GI effects Health and wellness professionals must understand these risks when evaluating any experimental protocols involving cagrilintide alongside other metabolic peptides

Weight loss rate gradually decreases from peak rates in weeks 8-16, but total progress continues steadily

These two mechanisms are shared with tirzepatide, which is a dual GLP-1/GIP agonist